emerg
virus
hiv
dengu
influenza
sar
coronaviru
ebola
virus
pose
signific
threat
human
health
major
virus
respons
outbreak
pathogen
lethal
infect
date
effect
therapeut
strategi
avail
prophylaxi
treatment
infect
chloroquin
analog
use
decad
primari
success
drug
malaria
concomit
emerg
chloroquineresist
plasmodium
strain
subsequ
decreas
use
antimalari
drug
applic
analog
investig
sinc
analog
interest
biochem
properti
drug
found
effect
wide
varieti
viral
infect
antivir
action
analog
shown
inhibit
acidif
endosom
event
replic
infect
moreov
immunomodulatori
effect
analog
benefici
patient
sever
inflammatori
complic
sever
viral
diseas
interestingli
one
success
target
strategi
inhibit
hiv
replic
analog
vitro
test
sever
clinic
trial
review
focus
potenti
chloroquin
analog
treatment
endosom
low
ph
depend
emerg
viral
diseas
emerg
reemerg
pathogen
ebola
marburg
virus
dengu
hepat
c
virus
sever
acut
respiratori
syndrom
sar
middleeast
respiratori
syndrom
mer
coronavirus
human
avian
influenza
virus
chikungunya
viru
chikv
human
immunodefici
viru
hiv
virus
repres
huge
challeng
human
veterinari
medicin
research
physician
healthcar
profession
work
togeth
evalu
pandem
potenti
plan
mitig
strategi
entri
host
virus
bind
surfac
molecul
plasma
membran
suscept
cell
macrophag
monocyt
dendrit
cell
endotheli
cell
hepatocyt
lead
intern
vesicl
traffic
endosomallysosom
pathway
kiss
et
al
shivanna
et
al
bekerman
einav
ekin
et
al
kraft
et
al
long
et
al
order
infect
suscept
cell
virus
requir
endosom
lysosom
acidif
acid
ph
depend
endosom
proteas
cleav
viral
glycoprotein
segment
cross
replic
event
chandran
et
al
marzi
et
al
without
endosom
acidif
cleavag
process
viral
replic
infect
abrog
martinson
et
al
shivanna
et
al
therefor
target
endosomallysosom
acidif
acid
ph
depend
proteas
therapeut
agent
highli
effect
combat
present
world
viral
epidem
success
viral
infect
result
local
system
releas
sever
cytokin
chemokin
reactiv
oxygen
speci
ro
nitric
oxid
mediat
villing
et
al
baiz
et
al
caus
gener
cell
death
gandini
et
al
meng
et
al
routi
et
al
immun
system
patient
abl
control
infect
patient
recov
though
convalesc
prolong
recov
patient
shown
produc
infecti
viru
month
clinic
symptom
disappear
howev
immun
system
patient
unabl
regul
infect
suscept
cell
infect
lead
excess
releas
cytokin
manifest
fatal
extens
necrot
cell
present
mani
organ
includ
liver
spleen
lymph
node
kidney
leroy
et
al
baiz
et
al
chloroquin
structur
analog
hydroxychloroquin
pamaquin
plasmoquin
primaquin
mefloquin
ferroquin
ferrocen
analog
chloroquin
use
decad
primari
success
drug
malaria
concomit
emerg
chloroquineresist
plasmodium
strain
subsequ
decreas
use
antimalari
drug
new
potenti
use
cheap
avail
analog
investig
due
immunomodulatori
effect
analog
use
secondari
drug
treat
varieti
chronic
autoimmun
diseas
eg
rheumatoid
arthriti
system
lupu
erythematosu
etc
tumor
nonmalari
infect
albari
recent
sever
effort
made
identifi
effect
inexpens
univers
avail
antivir
agent
sens
analog
suggest
antivir
agent
inhibit
replic
infect
geisbert
et
al
savarino
et
al
barrow
et
al
chloroquin
analog
diprot
weak
base
unproton
form
chloroquin
diffus
spontan
rapidli
across
membran
cell
organel
acid
cytoplasm
vesicl
endosom
lysosom
golgi
vesicl
therebi
increas
ph
albari
oral
administr
analog
readili
absorb
concentr
tissu
liver
spleen
kidney
albari
sever
fatal
virus
harbor
replic
infect
geisbert
et
al
cellular
level
tissu
chloroquin
becom
highli
concentr
acid
organel
lead
dysfunct
sever
enzym
eg
requir
proteolyt
process
posttransl
modif
viral
protein
fig
savarino
et
al
marzi
et
al
consequ
chloroquin
analog
inhibit
product
sever
cytokin
chemokin
mediat
whose
excess
appear
contribut
sever
viral
infect
therefor
inhibit
endosom
acidif
chloroquin
analog
may
becom
potenti
therapeut
strategi
viral
infect
associ
patholog
increas
evid
suggest
entri
replic
infect
process
sever
virus
ebola
marburg
dengu
chikungunya
hiv
etc
highli
depend
endosomallysosom
acidif
activ
sever
host
endosom
proteaseswhich
also
activ
acid
ph
environ
sun
tien
barrow
et
al
neutral
acid
ph
endosom
chloroquin
analog
inhibit
viral
entri
replic
process
cytoplasm
suscept
cell
therebi
abrog
infect
chiang
et
al
savarino
et
al
furthermor
dysfunct
variou
enzym
eg
glycosyl
enzym
glycosyltransferas
caus
increas
acid
ph
andor
structur
chang
golgi
apparatu
hydroxychloroquin
specif
interact
chloroquin
shown
suppress
glycosyl
sarscoronavirus
vincent
et
al
savarino
et
al
also
envelop
protein
result
structur
chang
glycoprotein
turn
reduc
reactiv
infect
newli
produc
virion
savarino
et
al
naard
et
al
sinc
surfac
glycoprotein
filovirus
ebola
marburg
involv
initi
infect
takada
et
al
yang
et
al
cytotox
yang
et
al
inhibit
glycosyl
analog
prevent
viral
entri
wide
varieti
host
cell
lead
suppress
pathogen
produc
noninfecti
decreas
infect
virus
inhibit
glycosyl
therefor
allow
time
adapt
immun
respons
deal
infect
baiz
et
al
antiinflammatori
immunomodulatori
action
chloroquin
analog
also
benefici
treatment
viral
infect
associ
patholog
albari
sever
studi
suggest
multipl
organ
failur
hypovolem
shock
observ
fatal
case
like
associ
direct
viral
infect
destruct
suscept
cell
eg
endotheli
cell
also
effect
proinflammatori
cytokin
chemokin
mediat
releas
infect
activ
cell
monocyt
macrophag
yang
et
al
baiz
et
al
marzi
et
al
geisbert
et
al
one
cytokin
strongli
implic
filovir
patholog
tumor
necrosi
factora
tnfa
abl
activ
macrophag
releas
mediat
ro
molecul
tnfa
cytokin
caus
increas
permeabl
infect
endotheli
cell
tracey
cerami
baiz
et
al
suggest
therapeut
agent
like
chloroquin
analog
abl
prevent
activ
macrophag
inhibit
secret
tnfa
variou
cell
clinic
relev
concentr
albari
would
confer
benefit
treatment
viral
infect
anoth
cytokin
interferonc
ifnc
also
implic
patholog
viral
infect
eg
ebola
report
ifnc
increas
cellular
sensit
apoptosi
upregul
express
fa
fa
ligand
schroder
et
al
fatal
case
ebola
infect
baiz
et
al
ifnc
also
take
part
massiv
apoptosi
stimul
monocytesmacrophag
produc
neopterin
baiz
et
al
concomit
deriv
murr
et
al
shown
plasma
concentr
neopterin
significantli
progress
increas
throughout
diseas
cours
ebola
infect
baiz
et
al
therefor
therapeut
agent
like
chloroquin
analog
inhibit
variou
cytokin
product
eg
ifnc
tnfa
neopterin
variou
cell
also
abl
prevent
activ
macrophag
baiz
et
al
albari
analog
may
becom
great
therapi
treatment
patient
infect
emerg
virus
adjuv
therapi
chloroquin
analog
regul
immun
activ
viral
infect
eg
antiretrovir
agent
analog
reduc
system
tcell
activ
murray
et
al
lerouxroel
et
al
routi
et
al
immun
hyperactiv
hivaid
savarino
shytaj
thu
analog
benefici
chronic
hivinfect
individu
endosom
inhibitor
chloroquin
block
tolllik
receptor
tlr
mediat
activ
plasmacytoid
dendrit
cell
pdc
myeloid
differenti
primari
respons
gene
signal
decreas
level
downstream
signal
molecul
receptor
associ
kinas
ifn
regulatori
factor
inhibit
ifna
synthesi
martinson
et
al
addit
suppress
pdc
activ
analog
also
block
neg
modul
tcell
indoleamin
ido
program
death
ligand
sinc
tlr
stimul
product
ifna
pdc
contribut
immun
activ
block
pathway
use
chloroquin
analog
interfer
emerg
viral
pathogenesi
martinson
et
al
product
entri
replic
aid
caus
agent
depend
endocyt
pathway
involv
acid
organel
endosom
lysosom
transgolgi
network
daeck
et
al
chauhan
et
al
mani
studi
focus
antihiv
activ
chloroquin
analog
eg
chloroquin
hydroxychloroquin
pamaquin
plasmoquin
primaquin
hiv
lerouxroel
et
al
martinson
et
al
mizuguchi
et
al
savarino
shytaj
vitro
chloroquin
analog
hydroxychloroquin
endow
broadspectrum
activ
clinic
achiev
concentr
lmoll
savarino
et
al
chloroquin
also
inhibit
postintegr
event
affect
newli
produc
viral
envelop
glycoprotein
vitro
chloroquin
exert
addit
effect
combin
antiretrovir
agent
eg
zidovudin
didanosin
hydroxyurea
without
cellular
toxic
apoptosi
savarino
et
al
sinc
chloroquin
hydroxychloroquin
appear
similar
site
action
ie
posttranscript
inhibit
drug
use
combin
antiretrovir
agent
treatment
infect
individu
develop
world
savarino
et
al
naard
et
al
hiv
inhibitor
chloroquin
alon
inhibit
hiv
replic
viral
particl
glycosyl
synerg
inhibitori
effect
proteas
inhibitor
indinavir
ritonavir
saquinavir
savarino
et
al
thu
suggest
use
chloroquin
analog
manag
routin
hiv
diseas
vivo
romanelli
et
al
parri
naard
et
al
transmiss
replic
tlymphocyt
reduc
presenc
chloroquin
suggest
analog
exert
activ
number
mechan
vivo
includ
modul
structur
naard
et
al
inhibitor
rout
entri
chloroquin
vagin
gel
formul
also
exert
activ
vitro
brouwer
et
al
pdc
cell
recogn
microbi
product
virus
via
produc
ifn
presenc
elev
ifna
level
hiv
infect
cell
lead
contribut
immun
activ
chloroquin
block
tlrmediat
activ
pdc
signal
decreas
level
downstream
signal
molecul
inhibit
ifna
synthesi
ewald
et
al
martinson
et
al
chloroquin
also
decreas
tcell
activ
induc
result
suggest
chloroquin
analog
prevent
role
hiv
pathogenesi
block
tlr
stimul
ifna
product
pathway
martinson
et
al
interestingli
recent
order
find
screen
evalu
antihiv
compound
cellpenetr
peptid
polyfunct
styryl
thiazolopyrimidin
analog
use
standard
drug
comparison
purpos
fatima
et
al
mizuguchi
et
al
vivo
use
chloroquin
hiv
posit
mother
associ
decreas
rate
vertic
transmiss
viru
infant
neeli
et
al
children
chloroquin
combin
zidovudin
didanosin
therapeut
potenti
infect
children
engchanil
et
al
increas
level
activ
cell
hallmark
chronic
hiv
infect
treatment
chloroquin
reduc
system
tcell
immun
activ
suggest
use
might
benefici
hivinfect
individu
murray
et
al
malaria
hiv
coinfect
coendem
wide
portion
world
remain
major
caus
morbid
mortal
unek
ogbonna
kraft
et
al
analog
offer
signific
advantag
current
therapi
due
lack
crossresist
antiretrovir
low
cost
romanelli
et
al
savarino
et
al
chloroquin
analog
inhibit
hiv
replic
glycosyl
limit
toxic
vitro
well
antivir
effect
analog
combin
antiretrovir
confirm
vivo
tabl
analog
attempt
use
sever
ongo
clinic
trial
tabl
recent
one
review
paper
suggest
ration
use
chloroquin
analog
counteract
immun
activ
hiv
infect
savarino
shytaj
howev
anoth
retrospect
review
confront
statement
dampen
immun
activ
analog
chauhan
tikoo
thu
analogbas
strategi
pursu
futur
studi
factor
must
taken
consider
doseand
dosag
form
select
start
time
treatment
etc
order
maxim
effect
analog
vivo
flavivirus
includ
hepat
c
viru
hcv
dengu
viru
affect
million
peopl
worldwid
estim
million
peopl
unit
state
virus
display
broad
spectrum
clinic
manifest
may
vari
asymptomat
sever
even
fatal
featur
dedania
wu
dengu
viral
envelop
glycoprotein
e
hcv
glycoprotein
play
import
role
attach
entri
cell
two
main
pathway
direct
fusion
plasma
membran
receptormedi
endocytosi
fusion
process
virus
facilit
low
ph
within
endosom
peng
et
al
matsuda
et
al
piccini
et
al
expos
acid
ph
contain
endosom
vesicl
target
cell
virus
rearrang
structur
conform
modif
envelop
glycoprotein
eg
trimer
dengu
glycoprotein
e
final
initi
replic
ashfaq
et
al
gandini
et
al
vausselin
et
al
bekerman
einav
increas
endosom
ph
chloroquin
inhibit
dengu
viru
type
replic
vero
cell
faria
et
al
cell
faria
et
al
nontox
dose
lgml
vitro
amodiaquin
one
drug
inhibit
replic
infect
ec
valu
lmoll
replicon
express
cell
boonyasuppayakorn
et
al
chloroquin
also
inhibit
membran
tnfrelat
apoptosisinduc
ligand
mtrail
reloc
ifna
product
pdc
vitro
vivo
gandini
et
al
chloroquin
interfer
replic
aotu
monkey
serum
concentr
tnfa
ifnc
statist
signific
reduc
vol
iss
page
chloroquin
treat
group
faria
et
al
sever
analog
chloroquin
attempt
use
sever
random
doubleblind
studi
outcom
therapi
shown
tabl
chloroquin
analog
also
reduc
hcv
entri
replic
infect
interf
endosom
acidif
treatment
differ
cell
chloroquin
suppress
entri
replic
hcv
dosedepend
manner
blanchard
et
al
mizui
et
al
chloroquin
show
reduct
infect
hcv
lmoll
concentr
liver
cell
ashfaq
et
al
furthermor
combin
treatment
chloroquin
ifna
enhanc
antivir
effect
ifna
prevent
repropag
hcv
mizui
et
al
ferroquin
ferrocen
analog
chloroquin
potent
inhibit
hcv
infect
hepatoma
cell
line
affect
earli
step
viral
life
cycl
addit
analog
also
inhibit
hcv
rna
replic
impair
fusion
process
analog
also
suppress
hcv
celltocel
spread
neighbor
cell
combin
analog
ifn
inhibitor
hcv
proteas
result
addit
synergist
activ
vausselin
et
al
reduc
acidif
endocyt
system
chloroquin
enhanc
human
cell
respons
solubl
viral
antigen
deriv
hcv
hepat
b
viru
hiv
vivo
accapezzato
et
al
case
report
suggest
patient
hcv
infect
associ
porphyria
cutanea
tarda
chloroquin
mg
twice
weekli
result
gradual
regress
skin
lesion
includ
porphyria
pellicelli
et
al
chikungunya
viru
chikv
mosquitotransmit
alphaviru
caus
acut
fever
character
longlast
arthralgia
affect
primarili
peripher
joint
human
sourisseau
et
al
taubitz
et
al
mechan
chikv
entri
infect
host
cell
indic
chikv
endocyt
aed
albopictu
cell
line
requir
low
phdepend
viral
membran
fusion
process
ozden
et
al
gay
et
al
treatment
strategi
chikv
infect
primarili
support
symptomat
although
gener
recommend
specif
antivir
therapi
use
chloroquin
ribavirin
interferonalpha
might
use
stock
mileston
fortun
chloroquin
analog
occur
sinc
open
pilot
studi
efficaci
chloroquin
treatment
chronic
chikv
arthriti
observ
indic
antimalari
treatment
improv
significantli
articular
index
morn
stiff
patient
chikv
infect
patient
improv
condit
brighton
result
lead
justifi
studi
chloroquin
chikv
infect
vitro
rang
chloroquin
analog
show
potenti
antivir
activ
chikv
kaur
chu
inhibitori
effect
observ
chloroquin
administ
preinfect
postinfect
concurr
infect
suggest
chloroquin
prophylact
therapeut
potenti
chloroquin
diminish
chikv
infect
dosedepend
manner
rang
effect
concentr
lmoll
maximum
inhibitori
effect
observ
within
h
postinfect
treatment
ineffect
viru
success
pass
acidif
pathway
earli
stage
infect
stock
kaur
chu
thu
start
time
treatment
dose
dose
regimen
chloroquin
import
consider
success
treatment
chikv
infect
vivo
chloroquin
poorli
activ
acut
chikv
infect
de
lamballeri
et
al
may
proper
prognosi
infect
initi
time
treatment
well
dose
regimen
chloroquin
establish
yet
orthomyxoviru
influenza
viru
iav
repres
major
threat
human
health
iav
enter
host
cell
clathrindepend
endocytosi
di
trani
et
al
wang
jiang
influenza
viral
surfac
glycoprotein
hemagglutinin
ha
also
facilit
viral
entri
host
cell
mediat
fusion
viral
membran
within
cellular
acid
compart
wu
et
al
thu
intravesicular
acid
ph
essenti
viralcel
fusion
process
vitro
chloroquin
abl
inhibit
iav
replic
lower
plasma
concentr
reach
treatment
acut
malaria
ooi
et
al
chloroquin
increas
endosom
ph
impair
iav
releas
cytosol
fedson
inhibitori
effect
chloroquin
maxim
drug
given
time
infect
lost
h
postinfect
di
trani
et
al
result
suggest
treatment
time
approxim
correspond
viruscel
fusion
moreov
clear
correl
ec
chloroquin
vitro
electrostat
potenti
ha
mediat
viruscel
fusion
process
thu
treatment
start
within
time
viruscel
fusion
process
exact
effect
concentr
although
vitro
result
promis
chloroquin
effect
prevent
therapi
vivo
standard
mous
ferret
model
human
iav
infect
vigerust
mcculler
recent
chloroquin
highli
effect
treat
avian
iav
infect
anim
model
yan
et
al
chloroquin
improv
cell
respons
mice
follow
singl
administr
influenza
vaccin
garulli
et
al
although
analog
report
effect
iav
vitro
use
invivo
experi
clinic
trial
prevent
treatment
influenza
paton
et
al
borba
et
al
effect
analog
antiinfluenza
drug
question
caution
use
recommend
wu
et
al
newcastl
diseas
viru
ndv
caus
agent
veterinari
diseas
bird
ndv
enter
cell
direct
fusion
viral
envelop
cellular
membran
low
phand
receptordepend
endocytosi
sanchezfelip
et
al
vitro
optim
ndv
infect
host
cell
significantli
affect
drug
chloroquin
inhibit
endosom
acidif
sanchezfelip
et
al
ndv
infect
induc
autophagi
inhibit
autophagi
analog
reduc
viral
replic
infect
meng
et
al
sun
et
al
importantli
pharmacolog
modul
autophagi
chloroquin
potenti
ndvmediat
oncolysi
mice
bear
cisplatinresist
lung
cancer
cell
jiang
et
al
filovirus
ebola
marburg
caus
sever
hemorrhag
fever
human
nonhuman
primat
peplom
ebola
virus
compos
trimer
heterodim
glycoprotein
heavili
glycosyl
nlink
olink
glycan
geisbert
et
al
glycoprotein
ebola
peplom
broad
tropism
varieti
host
cell
due
abil
bind
either
specif
nonspecif
variou
cell
surfac
molecul
facilit
phdepend
endosom
entri
host
cell
yang
et
al
yang
et
al
bhattacharyya
et
al
thu
despit
broad
tropism
infect
filovirus
greatli
depend
acid
ph
chandran
et
al
marzi
et
al
use
vitro
cell
cultur
assay
systemat
screen
fdaapprov
drug
inhibitor
biolog
threat
agent
ebola
marburg
virus
perform
found
chloroquin
noteworthi
antivir
compound
among
identifi
multipl
virusspecif
inhibitor
report
suggest
chloroquin
disrupt
viral
entri
replic
vitro
protect
mice
ebola
viru
challeng
vivo
madrid
et
al
long
long
et
al
confirm
chloroquin
capabl
inhibit
viral
entri
ph
specif
manner
consid
prioriti
candid
treatment
ebola
virus
later
report
suggest
chloroquin
inhibit
viru
replic
vitro
unabl
treat
patient
bishop
mous
hamster
falzarano
et
al
guinea
pig
dowal
et
al
sar
coronaviru
cov
recogn
infect
peopl
worldwid
fatal
rate
approxim
infect
target
cell
sarscov
mediat
interact
viral
spike
protein
cellular
receptor
angiotensinconvert
enzym
freund
et
al
mer
coronaviru
cov
infect
occur
phenomena
sar
human
except
cellular
entri
receptor
dipeptidyl
peptidas
li
et
al
raj
et
al
regist
effect
prophylact
postexposur
therapeut
treatment
coronavir
infect
current
avail
report
chloroquin
strong
antivir
effect
sarscov
infect
spread
vitro
keyaert
et
al
vincent
et
al
de
wild
et
al
addit
wellknown
function
chloroquin
elev
endosom
ph
drug
appear
interfer
termin
glycosyl
cellular
receptor
may
neg
affect
virusreceptor
bind
abrog
infect
ic
chloroquin
inhibit
sarscov
vitro
ae
lmoll
significantli
lower
cytostat
activ
approxim
plasma
chloroquin
concentr
reach
treatment
acut
malaria
interestingli
suppress
effect
observ
cell
treat
chloroquin
either
exposur
viru
suggest
prophylact
therapeut
advantag
keyaert
et
al
vincent
et
al
screen
librari
fdaapprov
drug
antimerscov
activ
cell
cultur
four
compound
chloroquin
chlorpromazin
loperamid
lopinavir
identifi
inhibit
viral
replic
effect
concentr
ec
lmoll
although
protect
activ
chloroquin
alon
combin
remain
assess
anim
model
find
may
offer
start
point
treatment
patient
infect
zoonot
coronavirus
like
merscov
de
wild
et
al
betanodavirus
causal
agent
viral
nervou
necrosi
mani
speci
marin
farm
fish
report
betanodavirus
enter
fish
cell
endocytosi
presenc
lmoll
chloroquin
inhibit
entri
infect
betanodavirus
vitro
adachi
et
al
felin
caliciviru
fcv
major
caus
agent
respiratori
diseas
cat
fcv
infect
cell
via
clathrinmedi
endocytosi
inhibitor
endosom
acidif
chloroquin
block
viral
permeabil
event
endosom
stuart
brown
treatment
chloroquin
significantli
reduc
replic
calicivirus
includ
porcin
enter
caliciviru
murin
felin
caliciviru
vitro
shivanna
et
al
borna
diseas
viru
bdv
mainli
seen
caus
agent
borna
diseas
hors
anim
exhibit
high
neurotrop
provid
import
experiment
model
system
studi
viruscel
interact
within
central
nervou
system
lysosomotrop
agent
includ
chloroquin
prevent
bdv
infect
indic
bdv
enter
host
cell
endocytosi
requir
acid
intracellular
compart
allow
membran
fusion
initi
infect
gonzalezdunia
et
al
clement
de
la
torr
chloroquin
analog
becom
potenti
candid
treatment
sever
emerg
viral
diseas
basi
inhibitori
effect
vitro
although
effect
prove
highli
reproduc
vivo
antivir
effect
analog
prove
limit
extent
sever
follow
reason
exist
failur
analog
becom
potenti
antiretrovir
agent
clinic
chloroquin
analog
hydroxychloroquin
ineffect
treat
low
phdepend
emerg
viral
infect
due
fail
attain
sustain
steadi
state
concentr
blood
suffici
increas
keep
ph
acid
organel
approxim
neutral
patient
viremia
becom
undetect
although
consider
intersubject
variabl
steadi
state
blood
concentr
chloroquin
analog
maximum
safe
serum
concentr
chloroquin
diphosph
ngml
maximum
safe
dose
mgkg
per
day
laaksonen
et
al
whole
blood
concentr
hydroxychloroquin
lgl
munster
et
al
howev
dose
dose
regimen
adjust
optim
benefitrisk
ratio
ration
basi
pharmacokinet
pharmacotoxicodynam
consider
moreov
plasma
level
chloroquin
analog
depend
factor
methodolog
well
storag
condit
sampl
analog
trap
erythrocyt
lymphocyt
platelet
chloroquin
also
racem
mixtur
report
kinet
behavior
separ
enantiom
differ
human
augustijn
et
al
noth
know
relev
stereospecif
therapi
emerg
viral
infect
pharmacokinet
paramet
consider
chloroquin
disput
narrow
therapeut
index
poor
penetr
specif
tissu
augustijn
et
al
report
differ
efficaci
toxic
chloroquin
analog
hydroxychloroquin
longterm
effect
rheumatoid
diseas
avinazubieta
et
al
rheumatoid
arthriti
therapi
report
hydroxychloroquin
one
half
twothird
effect
chloroquin
one
half
toxic
tobin
et
al
mackenzi
thu
hydroxychloroquin
gener
regard
safe
reason
effect
less
toxic
treatment
rheumatoid
diseas
recommend
daili
dose
mgkg
per
day
maximum
dose
mgday
suggest
blood
concentr
desethylhydroxychloroquin
one
oxid
metabolit
hydroxychloroquin
relat
treatment
efficaci
blood
hydroxychloroquin
concentr
associ
toxic
munster
et
al
thu
select
chloroquin
analog
metabolit
also
import
factor
success
treatment
viral
diseas
chloroquin
analog
combin
antivir
drug
consid
effect
treatment
viral
diseas
order
avoid
interact
pglycoprotein
multidrugresist
associ
protein
vol
iss
page
virus
extrud
drug
cell
anatom
compart
savarino
also
note
combin
drug
must
interact
analog
zhou
et
al
maximum
inhibitori
effect
chloroquin
analog
observ
immedi
start
treatment
ineffect
viru
success
pass
replic
event
stock
kaur
chu
also
note
efficaci
chloroquin
analog
markedli
depend
acut
stage
sever
infect
de
lamballeri
et
al
thu
start
time
treatment
dose
dose
regimen
therapeut
load
dose
subsequ
mainten
dose
achiev
steadi
state
blood
chloroquin
concentr
import
factor
efficaci
viral
infect
hope
exact
chloroquin
analog
improv
pharmacokinet
abl
bridg
gap
effect
invitro
invivo
effect
futur
sinc
inhibit
acidif
endosom
replic
cours
emerg
virus
chloroquin
analog
report
endow
wide
rang
viral
diseas
includ
hiv
follow
consequ
taken
consider
chloroquin
inhibit
viral
entri
replic
infect
analog
exert
inhibitori
effect
sever
opportunist
pathogen
includ
virus
aid
analog
exert
inhibitori
effect
synthesi
sever
proinflammatori
cytokin
may
play
pathogen
role
progress
viral
infect
drug
potenti
restrict
iron
accumul
variou
tissu
may
play
neg
role
viral
infect
analog
practic
advantag
wide
distribut
inexpens
stigmat
analog
may
potenti
benefit
decreas
rate
mothertochild
transmiss
virus
like
hiv
base
result
variou
vitro
studi
suggest
chloroquin
analog
amelior
infect
low
ph
depend
virus
although
outcom
clinic
trial
impress
tabl
analog
potenti
clinic
efficaci
viral
infect
sever
clinic
trial
still
ongo
attempt
establish
use
chloroquin
analog
prevent
treatment
sever
viral
infect
includ
hiv
hepat
rabi
chikungunya
ebola
viru
diseas
influenza
b
dengu
viral
infect
tabl
review
tri
establish
bridg
gap
promis
vitro
result
chloroquin
analog
broad
spectrum
antivir
mix
disappoint
result
obtain
sever
anim
model
clinic
trial
mani
factor
get
feasibl
solut
bridg
gap
exert
antivir
effect
sustain
releas
dosag
form
modif
maintain
continu
steadi
state
level
chloroquin
analog
select
suitabl
analog
combin
therapi
prevent
dosag
form
eg
vagin
gel
antihiv
recent
number
track
suitabl
chloroquin
analog
investig
inhibit
viral
enzym
viru
entri
matur
enhanc
immunolog
respons
new
anim
model
made
avail
includ
mous
model
nonhuman
primat
model
develop
better
therapi
viral
diseas
along
comput
model
might
help
dock
target
molecular
featur
respons
antivir
activ
chloroquin
analog
eg
target
ebola
virus
analog
ekin
et
al
hypothes
use
therapeut
well
clinic
trial
much
doubleblind
placebocontrol
random
trial
necessari
justif
use
chloroquin
analog
next
come
emerg
viral
treatment
author
would
like
acknowledg
british
societi
antimicrobi
chemotherapi
bsac
inspir
previou
review
paper
author
wish
confirm
known
conflict
interest
associ
public
financi
support
work
could
influenc
outcom
author
also
declar
receiv
assist
profession
medic
writer
similar
servic
thu
state
none
declar
diseas
vivo
guinea
pig
model
j
gen
virol
ekin
freundlich
js
coffe
common
featur
pharmacophor
fdaapprov
drug
inhibit
ebola
viru
engchanil
c
kosalaraksa
p
lumbiganon
p
lulitanond
v
pongjunyakul
p
thuennade
r
et
al
therapeut
potenti
chloroquin
ad
zidovudin
plu
didanosin
infect
children
j
med
assoc
thai
